Christopher B. Cooper, PhD
Founder & Principal Consultant
Dr. Christopher Cooper is an accomplished pharmaceutical R&D executive with more than 35 years of experience spanning medicinal chemistry, translational science, preclinical development, CMC, and regulatory strategy. His career includes leadership roles at Pfizer, Bristol-Myers Squibb, and TB Alliance, where he directed global discovery and development programs across multiple therapeutic areas.
Dr. Cooper has played a central role in advancing over two dozen drug discovery and development programs, including:
Multiple clinical candidates advanced into Phase I and Phase II
Pretomanid, a first-in-class antitubercular drug approved by the FDA and EMA
Authoring six IND (3.2.S) submissions and one NDA/MAA (3.2.S) for pretomanid
Oversight of 70+ FTE across chemistry, API development, and CMC operations globally
Leadership of 26+ discovery, translational, and clinical-stage programs across infectious disease, oncology, metabolic disease, immunology, and more
He is the author of 58 scientific publications, 18 patents, and a frequent invited speaker at medicinal chemistry and drug development conferences worldwide. Dr. Cooper has served on Scientific Advisory Boards for leading academic institutions and global health initiatives, including the Eli Lilly TB Drug Initiative and the Weill Cornell TB Research Unit.
Recognized for his ability to bridge deep scientific expertise with clear, strategic leadership, Dr. Cooper brings a unique, high-value perspective to organizations seeking to accelerate innovation and strengthen R&D decision-making.